Hobara Takahiro, Ando Masahiro, Higuchi Yujiro, Yuan Jun-Hui, Yoshimura Akiko, Saito Takashi, Shiihara Takashi, Okuda Shiho, Fukushima Naoki, Awano Hiroyuki, Inoue Takahito, Yano Chikashi, Kojima Fumikazu, Kodama Kento, Hiramatsu Yu, Nozuma Satoshi, Nakamura Tomonori, Sakiyama Yusuke, Hashiguchi Akihiro, Mitsui Jun, Tsuji Shoji, Takashima Hiroshi
Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.
Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
J Neurol. 2025 Jul 16;272(8):514. doi: 10.1007/s00415-025-13243-5.
Giant axonal neuropathy 1 (GAN) is a rare neurodegenerative disorder with autosomal recessive inheritance and significant phenotypic heterogeneity, ranging from milder presentations resembling Charcot-Marie-Tooth disease (CMT) to classical presentations involving central and peripheral nervous systems. We investigated the genetic and clinical spectrum of GAN in Japanese patients with inherited peripheral neuropathies (IPNs).
We conducted genetic screening of 3315 Japanese patients diagnosed with IPNs between 2007 and 2023 using targeted next-generation or whole-exome sequencing. Variant pathogenicity, clinical features, and neurophysiological and neuroimaging findings were reviewed.
We identified seven biallelic GAN variants in five patients from four unrelated families, including one homozygous and three compound heterozygous genotypes. Two novel pathogenic variants were identified: c.922G > T (p.Glu308*) and c.456dup (p.Ala153Cysfs*27). Two families exhibited the classical phenotype, whereas the other two exhibited a CMT-like phenotype. Mean onset age was 4.4 years (range 1.5-8), and gait disturbance was the initial symptom. The most common findings included distal weakness (n = 5), sensory impairment (n = 4), scoliosis (n = 3), autonomic dysfunction (n = 2). Neurophysiologically, all patients had sensorimotor axonal polyneuropathy. One patient with mild phenotype maintained a CMT-like state without systemic involvement until the age of 43 years and was still alive at 72, representing the longest documented survival in GAN.
This study expands the genetic and phenotypic spectrum of GAN by identifying novel variants and a long-term survivor. These findings underscore the importance of systematic genetic screening for GAN in pediatric-onset CMT, even in the absence of classical features.
巨轴索神经病1型(GAN)是一种罕见的神经退行性疾病,具有常染色体隐性遗传,且表型显著异质性,从类似夏科-马里-图斯病(CMT)的较轻表现到涉及中枢和周围神经系统的典型表现不等。我们调查了日本遗传性周围神经病(IPN)患者中GAN的遗传和临床谱。
我们对2007年至2023年间诊断为IPN的3315名日本患者进行了靶向二代测序或全外显子组测序的基因筛查。对变异致病性、临床特征以及神经生理学和神经影像学结果进行了回顾。
我们在来自四个无关家庭的五名患者中鉴定出七个双等位基因GAN变异,包括一个纯合子和三个复合杂合子基因型。鉴定出两个新的致病变异:c.922G>T(p.Glu308*)和c.456dup(p.Ala153Cysfs*27)。两个家庭表现出典型表型,而另外两个家庭表现出CMT样表型。平均发病年龄为4.4岁(范围1.5 - 8岁),步态障碍是首发症状。最常见的表现包括远端无力(n = 5)、感觉障碍(n = 4)、脊柱侧弯(n = 3)、自主神经功能障碍(n = 2)。神经生理学上,所有患者均有感觉运动轴索性多神经病。一名表型较轻的患者在43岁之前维持CMT样状态且无全身受累,72岁时仍然存活,这是GAN有记录的最长生存期。
本研究通过鉴定新变异和一名长期存活者,扩展了GAN的遗传和表型谱。这些发现强调了即使在没有典型特征的情况下,对儿童期发病的CMT进行GAN系统基因筛查的重要性。